Saturday, 31 October 2026European Markets

INCLUSIO SA/NV And VGP Have A High Dividend Yield And Return On Equity In The Real Estate Services Industry.

Loading stream...

(VIANEWS) - INCLUSIO SA/NV (INCLU.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Real Estate Services industry.

Financial Asset Price Forward Dividend Yield Return on Equity
INCLUSIO SA/NV (INCLU.BR) €15.20 4.95% 16.47%
VGP (VGP.BR) €91.00 3.25% 8.79%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. INCLUSIO SA/NV (INCLU.BR)

4.95% Forward Dividend Yield and 16.47% Return On Equity

Inclusio SA operates as a real estate company in Belgium. It focuses on affordable rental housing, housing for disabled, and social infrastructures. Inclusio SA was incorporated in 2011 and is based in Brussels, Belgium.

Earnings Per Share

As for profitability, INCLUSIO SA/NV has a trailing twelve months EPS of €4.5.

PE Ratio

INCLUSIO SA/NV has a trailing twelve months price to earnings ratio of 3.38. Meaning, the purchaser of the share is investing €3.38 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.47%.

More news about INCLUSIO SA/NV.

2. VGP (VGP.BR)

3.25% Forward Dividend Yield and 8.79% Return On Equity

VGP NV, together with its subsidiaries, develops, owns, and manages logistics and semi-industrial real estate, and ancillary offices. It leases its properties to tenants in the logistic sector, including storing, assembling, re-conditioning, and final treatment of the goods. The company also provides property management services; asset management services related to corporate administration, financing, business planning, reporting, budgeting, management of tax and legal affairs, controlling, etc.; project management and leasing services; and facility management services, such as maintenance, waste management, and greenery maintenance services. It operates in Germany, Spain, France, Italy, the Netherlands, Austria, Portugal, the Czech Republic, Slovakia, Hungary, Romania, Serbia, and Latvia. VGP NV was founded in 1998 and is headquartered in Antwerp, Belgium.

Earnings Per Share

As for profitability, VGP has a trailing twelve months EPS of €7.12.

PE Ratio

VGP has a trailing twelve months price to earnings ratio of 12.78. Meaning, the purchaser of the share is investing €12.78 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.79%.

Volume

Today's last reported volume for VGP is 1669 which is 88.37% below its average volume of 14358.

Moving Average

VGP's value is below its 50-day moving average of €95.13 and way below its 200-day moving average of €101.78.

Revenue Growth

Year-on-year quarterly revenue growth grew by 131.6%, now sitting on 195.04M for the twelve trailing months.

More news about VGP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com